A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

• Status: Completed
• Trial end date: 1969-12-31

Summary

This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).

• Phase: Phase 2

Details

• Lead Sponsor: Genentech, Inc.
• Treatments: Adalimumab; Antirheumatic Agents; Leflunomide; Methotrexate